Evidence map›Paper›PMID 26544512›Full record

Trial reportOncotarget2015

NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance.

Anna Martner, Anna Rydström, Rebecca E Riise, Johan Aurelius, Mats Brune, Robin Foà, Kristoffer Hellstrand, Fredrik B Thorén

Open access · diamondAbstract readClinical Trial, Phase IVMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 42 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Microgravity and immune cells.Journal of the Royal Society, Interface · 2023
    Review
  14. Review
  15. Advances in NK cell production.Cellular & molecular immunology · 2022
    Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Anna MartnerTIMM Laboratory, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg 405 30, Sweden.
Anna RydströmTIMM Laboratory, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg 405 30, Sweden.
Rebecca E RiiseTIMM Laboratory, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg 405 30, Sweden.
Johan AureliusTIMM Laboratory, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg 405 30, Sweden.
Mats BruneDepartment of Hematology, University of Gothenburg, Gothenburg 413 45, Sweden.
Robin FoàDepartment of Cellular Biotechnologies and Hematology, Sapienza University of Rome, Rome 00161, Italy.
Kristoffer HellstrandTIMM Laboratory, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg 405 30, Sweden.
Fredrik B ThorénTIMM Laboratory, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg 405 30, Sweden.
University of Gothenburg · SESahlgrenska University Hospital · SESapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In a phase IV trial, eighty-four patients (age 18-79) with acute myeloid leukemia (AML) in first complete remission (CR) received cycles of immunotherapy with histamine dihydrochloride (HDC) and low-dose human recombinant interleukin-2 (IL-2) to prevent relapse in the post-consolidation phase. Aspects of natural killer (NK) cell biology were analyzed before and during immunotherapy with focus on outcome in older patients. In younger (<60 years old, n = 37) and older patients (>60 years old, n = 47), treatment with HDC/IL-2 resulted in an expansion of CD56(bright) and CD16+ NK cells in blood along with an increased NK cell expression of the natural cytotoxicity receptors (NCR) NKp30 and NKp46. In older patients, a high expression of NKp30 or NKp46 on CD16+ NK cells before and during therapy predicted leukemia-free and overall survival. These results suggest that NK cell functions determine relapse risk and survival in older AML patients and point to biomarkers of efficacy in protocols for remission maintenance.

Indexed as

AdolescentAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCD56 AntigenFemaleFlow CytometryGPI-Linked ProteinsHistamineHumansImmunotherapyInterleukin-2Kaplan-Meier EstimateKiller Cells, NaturalLeukemia, Myeloid, AcuteLymphocyte SubsetsaldesleukinCD56 AntigenFCGR3B protein, humanGPI-Linked ProteinsHistamineInterleukin-2Natural Cytotoxicity Triggering Receptor 1Natural Cytotoxicity Triggering Receptor 3NCAM1 protein, humanNCR1 protein, humanNCR3 protein, humanReceptors, IgGRecombinant Proteinsacute myeloid leukemiaImmune responseImmunityImmunology and Microbiology Sectionimmunotherapynatural killer cellsNKp30NKp46

Identifiers

PMID26544512
PMCPMC4767453
OpenAlexW2253196802

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.